Aronson D L, Stevan L, Ball A P, Franza B R, Finlayson J S
J Clin Invest. 1977 Dec;60(6):1410-8. doi: 10.1172/JCI108902.
We have investigated the pathway of prothrombin activation in blood and plasma. By means of a rapid purification procedure involving chromatography on DEAE-cellulose and hydroxyapatite, we demonstrated that the major prothrombin fragment in serum is that representing the amino-terminal half of prothrombin (i.e. F1-2). The F1-2 isolated was characterized by its size, amino acid and antigenic compositions, amino-terminal residue, and the peptides (designated F1 and F2, respectively) it yielded upon hydrolysis by thrombin. Measurements by the isotope dilution technique showed that F1-2 could account for the fate of at least 90% of the prothrombin originally present in plasma. By contrast, the serum concentration of the fragment representing the amino-terminal third of prothrombin (viz. F1) was less than 10% that of F1-2. These results demonstrated that the major route of prothrombin conversion in blood or plasma involves the removal of the combined activation fragment (F1-2) as a single peptide.
我们研究了血液和血浆中凝血酶原激活的途径。通过一种涉及在DEAE-纤维素和羟基磷灰石上进行色谱分离的快速纯化程序,我们证明血清中的主要凝血酶原片段是代表凝血酶原氨基末端一半的片段(即F1-2)。分离出的F1-2通过其大小、氨基酸和抗原组成、氨基末端残基以及经凝血酶水解后产生的肽段(分别命名为F1和F2)进行表征。通过同位素稀释技术测量表明,F1-2可以解释血浆中最初存在的至少90%的凝血酶原的去向。相比之下,代表凝血酶原氨基末端三分之一的片段(即F1)的血清浓度不到F1-2的10%。这些结果表明,血液或血浆中凝血酶原转化的主要途径涉及作为单个肽段去除组合的激活片段(F1-2)。